December 17, 2008 Harold F. Farber, M.D. Home Address: 190 Presidential Blvd. Unit 615 Bala Cynwyd, PA 19004 Office Addresses: 822 Montgomery Avenue
Education: 1975-79BA Penn State University 1979-83 MD Albany Medical College Postgraduate Training and Fellowship Appointments: 1983-84 – Intern in Medicine, Albany Medical Center 1984-87 – Resident in Dermatology, Thomas Jefferson University Hospital Faculty Appointments: 1994 – Present – Attending Physician, Hahnemann University Hospital 1995 – Present – Attending Physician, Lankenau Hospital Specialty Certification: 1987 American Board of Dermatology Licensure: Pennsylvania Awards, Honors & Membership in Honorary Society 1977 Phi Beta Kappa 2001 Main Line Top Doctors 2007 & 2008 To American’s Top Physicians Award 2008 Main Line Top Doctors Membership in Professional and Scientific Societies: American Medical Association Pennsylvania Medical Society American Society for Dermatologic Surgery Philadelphia County Medical Society American Academy of Dermatology Pennsylvania Academy of Dermatology Philadelphia Society of Facial Plastic Surgeons Dermatology Foundation American Academy of Cosmetic Surgery Thomas Jefferson University – Volunteer Faculty Member Council for Nail Disorders Medical Mycological Society of Americas Photomedicine Society Golden Slipper Club and Charities
Albany Medical College Mentor Program for Students on Career Related Issues American Society of Dermatologic Surgeons Independence Blue Cross Medical Policy Consultant Teaching In Office Lankenau Residents Arcadia University Physician Assistant Program Mentoring of College Alma Mater (Penn State University – pre medical students) Lectures: Guest Lecturer Wills Eye Institute Continuing Medical Education. Eyelid and Facial Rejuvenation; A Multidisciplanary Approach 04/08 Guest Lecturer at a Patient Education Seminar in the Use of New Therapeutic Treatments for Psoriasis at Huntingdon Valley, PA Participant in a Raptiva Speaker Training Seminar Norvartis Pharmaceuticals Presentation to Family Practitioners: Usage of Topical Immunomodulators in Dermatology Participant: Novartis consultant Network Regional Advisory Committee Participant: Genetech Regional Advisory Board Meeting: “Usage of Biologics in Psoriasis” Warner-Chilcott Pharmaceuticals Lecturer to Dermatology Physicians and Physician Assistants. “Acne Case Studies in Dermatology” Speaker for Novartis in “Advances in the Treatment of Atopic Dermatitis” (06/04) Guide to America’s Top Physicians” Consumers Research Council of America Recipient Award Main Line Today “Top Docs” Choice Award Warner Chilcott Speakers Bureau/Guest Lecturer – Doxycycline antibiotics in the Treatment of Acne Seminars in Psoriasis Speakers Participant Faculty Member International CME Lecture Series Aventis Pharmaceuticals Inc. Speaker Participant – Antihistamine Usage in Dermatology Novartis Consultant Network Participant and Guest Lecturer on Topical Immunomodulator usage in Eczema to Family Practitioners and Dermatologists Amgen Regional Speakers Training Participant Connections Magazine Dermatologic Consultant Pennsylvania Osteopathic Family Physicians Society Invited Guest Lecturer on Therapeutic Advances in the Treatment of Eczema 9/02 Covance Health Economics and Outcomes Services Inc. – Consultant Participant Physician Satisfaction and Payor coverage and Reimbursement for treatments using the Levulan Kerastick Fujisawa Dermatology Speakers Update Meeting Participant and Lecturer 6/02 Galderma Laboratories Speakers Program Participant/Speaker forum 6/02 Connetics Consultant Dermatology Advisory Meeting Connetics, OLUX Investigator Meeting Participant Connetics Speakers Training Meeting Participant Novartis Advisory Board Speaker – Understanding the Changing Landscape of Eczema Treatment for Family Practitioners/Internal Medicine 5/02 Novartis Pharmaceutical Famvir Speaker Training Meeting Particpant – AZ 2/02 Novartis Advisory Board Speaker
Topical Immunomodulator usage in Eczema.
2. Antiviral therapy for Herpetic Infections. 3. Onychomycosis: Treating and Managing Your Diabetes and other High Risk Patients, Family Practitioners Audience 2/02.
Elidel Speakers Training Meeting Participant Cutivate Speakers Training Meeting Participant Fujisawa Dermatology Visiting Faculty Program Lecturer, Multiple presentations Including: Pennsylvania, California, Utah, North Carolina, Maine, and Illinois lectures Purdue Pharmaceutical L.P. Speakers Bureau Member Novartis Pharmaceuticals Corporation Preceptor Guest Lecturer: Protopic: Safety, Efficacy, and Realistic Expectations. San Diego Dermatology Meeting (10/01)
Guest Lecturer: Differential Diagnosis and Management Issues Regarding Atopic Dermatitis. Philadelphia Family Physicians Dinner Meeting (09/01) Guest Lecturer: Diagnostic and Therapeutic Options in the Treatment of Onychomycosis Philadelphia Family Physicians Dinner Meeting (09/01) Guest Lecturer: Therapeutic Advancement in the Treatment of Eczema. Fujisawa Corporation New Jersey (08/01) Guest Lecturer: Safety, Efficacy, Study Design and Clinical Usage of Tecrolimus in the Treatment of Atopic Dermatitis. Fujisawa Corporation. Philadelphia (07/01) Guest Lecturer: Onychomycosis – Therapeutic Options. Novartis Pharmaceuticals. Phildelphia (04/01) Guest Lecturer: Clinical Experience using Current Antiviral Therapy. Novartis Pharmaceuticals. Philadelphia (2/01) Consultant Preceptor Bristol-Meyers Squibb Company for Sales Representative Training (04/01) Guest Lecturer: Clinical Experience, Efficacy and Alternatives to Lamisil and Famvir usage in an active Clinical Dermatology Practice. Philadelphia (06/01) Participated in Advisory Board Meeting for Managed Care evaluation of Fujisawa’s new product for Atopic Dermatitis (01/01) Philadelphia Dermatology Society invited guest lecturer monthly meeting. A noval treatment for pre cancerous Keratosis-Phase III Clinical Trial Results (01/01) Guest Lecturer on Photodynamic Treatment of Actinic Keratosis at Palm Beach Dermatology Society (12/00) Guest Lecturer in Boston for “Review & Results” of Phase III Clinical Trial in Photodynamic Treatment of Actinic Keratosis Guest Lecturer on Photodynamic Treatment of Actinic Keratosis at Broward County Dermatology Society (12/00) Connetics Corportion National Speakers’ Bureau – Lecture on Safe and Effective Usage of Topical Steroids (10/00) Novartis Pharmaceuticals Lecture on Current Treatment of Onychomycosis (08/00) SmithKline Beecham Lecture on Famvir and Common Skin Dermatoses (06/00) BioGlan Pharma Drug Representative Training Program Lecturer (1/00) BioGlan Pharma Physician Advisory Board Participant WPEN Radio “Ask the Doctor” Medical Guest on Dermatology Procedures AIDS Fund Medical Expert Participant for Tretment of Alopecia (ll/99) SmithKline Drug Representative Training Program Lecturer on Famcyclovir Schering Local Clinical Lecture Series to Pharmacists,; Exposure to Dermatology Schering Local Clinical Lecture Series to Medical Residents; Common Skin Dermatoses Schering Local Clinical Lecture Series to Family Practitioners; Dermatoses in General Practice American Society of Laser Medicine and Surgery, Guest Speaker on 810 nm Diode Laser Theory, Procedure, Results Guest Lecturer at Pennsylvania Academy of Dermatology (9/86) Cover Article – Philly Health and Fitness Magazine, “Philly’s Fittest Physicians” National Disease and Therapeutic Index Physician Panel Profile Participant National Ambulatory Medical Care Survey Participant Fujisawa Guest Lecturer on Eczema Central Valley Dermatology Society, “Clinical Safety and Effect of Protopic Use in Eczema from Multiple Clinical Trials” IMS Health Pharmaceutical Promotion Survey Participant Cynosure Guest Lecturer on A Dermatological Conversation on Fractional Resurfacing Technology. The Pyramid Club, Philadelphia, PA (06/20/07) Guest Lecturer on Steroid Responsive Dermatoses. Hahnemann University Hospital Residents. Tequila Restaurant, Philadelphia, PA (11/07/07) Volunteer – Olay Skin Cancer Public Screening Participant (2007) Guest Lecturer on Current Issues in Dermatology. Thomas Jefferson University Hospital Residents. Susanna Foo Restaurant, Philadelphia, PA (01/23/08) Warner Chilcott Guest Lecturer on Acne Therapeutics. Borgata Hotel, Atlantic City, NJ (07/18/08) Warner Chilcott Guest Lecturer on Psoriasis Therapeutics (08/01/08)
Bibliography: Publications, Peer reviewed: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. 345(4):248-55, 2001 Jul 26. Etanercept as monotherapy in patients with psoriasis.349(21):2014-22, 2003 Nov 20. Daniel J. Piacquadio; Diana M. Chen; Harold F. Farber; Joseph F. Fowler, Jr; Scott D. Glazer; J. John Goodman; Luciann L. Hruza; Edward W. B. Jeffes; Mark R. Ling; Tania J. Phillips; Tena M. Rallis; Richard K. Scher; Charles R. Taylor; Gerald David Weinstein Photodynamic Therapy With Aminolevulinic Acid Topical Solution and Visible Blue Light in the Treatment of Multiple Actinic Keratoses of the Face and Scalp: Investigator-Blinded, Phase 3, Multicenter Trials Arch Dermatol. 140(1):41-46, 2004. Farber, Harold F. Removal of a Spider angioma with Diode Laser Photoderm: Clinical Study and Photography Techniques for Dermatologist . Vol 2, No 2, 7-9, 2000. Massive lipoma of the palm. 11(5):431-3. 1983 Nov. Publications, Non-Peer reviewed:
Norton,L and Farber,H. Point-Counterpoint: Should Dermatologists Dispense Cosmetics - Skin and Aging Journal of Geriatric Dermatology, Vol 6, Number 1, 74-77, 1998 Clinical Research: Principal Investigator: Open-Label, Multi-Center Study to Evaluate the Transition from XXXXXX Therapy to Approved Systemic and/or Phototherapy Psoriasis Treatments in Adults with Moderate to Severe Plaque Psoriasis. Principal Investigator: A Multicenter, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study to Determine the Therapeutic Equivalence of Two XXXXXX 0.75% Gel Formulations in Subjects with Rosacea. Principal Investigator: A Multicenter, Randomized, Placebo-Controlled Phase 2 Study Evaluating the Effect of 2 mg, 15mg or 50 mg XXXXXX Treatment Compared to Placebo in Patients with Psoriasis. Principal Investigator: A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of l.0 mg/kg Subcutaneously Administered XXXXXX in Adults with Moderate to Severe Plaque Psoriasis who are candidate for Systemic Therapy. Principal Investigator: An Open-label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered XXXXXX in Adults with Plaque Psoriasis Previously Enrolled in Study XXXXXXX Principal Investigator: A Multi-Center, Community-Based Trial to Assess the Efficacy and Safety of XXXXXXX Cream in the Treatment of Facial Melasma
Principal Investigator: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXXXX 0.12% in the Treatment of Moderate to Severe Atopic Dermatitis Principal Investigator: Multicenter Dosing Ranging Study of the Safety and Efficacy of XXXXX in Psoriasis Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Exploratory Pharmacogenomic Study of Recombinant Human Interleukin Eleven (rhIL-11) in Patients with Active Psoriasis Principal Investigator: A Phase II Multicenter, Randomized, Investigator-Blinded Study to Evaluate the Safety and Efficacy of XXXXX, 1%, versus Vehicle Foam and XXXXX Topical Gel, 1%, in Subjects with Acne Vulgaris Principal Investigator: A Phase IIIb, Randomized, Double Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered XXXXX in Adults with Moderate to Severe Plaque Psoriasis Principal Investigator: Phase I Multiple-Dose, Dose-Escalation Study to Evaluate the Safety of XXXXX Administered by Subcutaneous Injection to Patients with Plaque Psoriasis Principal Investigator: Phase I-II Open-Label, Multiple Dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of XXXXX in Patients with Psoriasis Principal Investigator: A Phase III, Randomized, Double Blind, Parallel-Group, Placebo- Controlled, Multicenter, Multidose Study to Evaluate the Efficacy and Safety of Subcutaneously Administered XXXXX in Adults with Moderate to Severe Plaque Psoriasis who are candidates for Systemic Therapy Principal Investigator: Efficacy and Safety Comparison of XXXXX Cream vs Two Trials of Filters (XXXXX) in Patients with Polymorphous Light Eruption in Outdoor Conditions Principal Investigator: A Comparative Study of Inter-rater and Intra-rater Variability of Psoriasis Area and Severity Index (PASI), Psoriasis Global Assessment (PGA), and Lattice System Global Psoriasis Score (LSGPS) in Subjects with Active Psoriasis Principal Investigator: An Open-Label Study to Detertmine the Tolerability and Efficacy of Repeat Courses of XXXXX in Subjects with Chronic Plaque Psoriasis Principal Investigator: A Randomized, Double-Blind Comparison of Intravenous XXXXX vs Placebo in Subjects with Chronic Plaque Psoriasis Principal Investigator: A Blinded, Multiple-Dose Study to Determine the Tolerability of Repeated Courses of XXXXX in Subjects with Moderate, Moderate to Severe, and Severe Plaque Psoriasis Principal Investigator: A Phase II/III Multi-Center, Double-Blind, Parallel-Group, Efficacy and Safety Study of Once-A-Day Topical Administration of Three Concentrations of XXXX Compared to XXXXX in Subjects with Plaque Psoriasis Principal Investigator: An Open-Label, Long Term Study of the Safety and Tolerability of Oral XXXXX in Patients with Plaque Psoriasis Principal Investigator: A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Clinical Equivalence of XXXXX in Patients with Moderate to Severe Ichthyosis Vulgaris
Principal Investigator: An Open-Label Study to Evaluate the Safety of Topically Applied XXXXX Ointment for Treatment to Atopic Dermatitis Consultant Diomed Labs: Development and Application with Specific Criteria and Usage of Diode Laser in a Clinical Setting Principal Investigator: A Phase III Study of Photodynamic Therapy with XXXXX Topical Solution and Visible Blue Light in the Treatment of Multiple Actinic Keratoses Principal Investigator: A Phase III, Randomized, Double-Blind Study Comparison of Topically Applied XXXXX Ointment vs Vehicle Ointment in Adult Patients with Atopic Dermatitis Principal Investigator: A Parallel-Arm, Double Blind, Placebo-Controlled, Efficacy Study of XXXXX Lotion (12%) and Lac-Hydrin in Patients with Moderate or Greater Ichthyosis Vulgaris Principal Investigator: Open-Label, Long Term, Follow-Up Study to Evaluate the Safety of Topically Applied XXXXX Ointment for the Treatment of Atopic Dermatitis Principal Investigator: Double-Blind, Randomized, Parallel, Placebo-Controlled, Multi- Center Study to Evaluate the Safety and Clinical Equivalence of a Generic XXXXX vs XXXXX in Patients with Moderate to Severe Ichthyosis Vulgaris Principal Investigator: A Blinded, Multiple-Dose Study to Determine the Tolerability of Repeated Courses of XXXXX in Subjects with Moderate, Moderate to Severe, and Severe Plaque Psoriasis Principal Investigator: An Open-Label Study to Determine the Safety and Efficacy of Repeated Courses of XXXXX in Subjects with Chronic Plaque Psoriasis Investigator: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Multicenter Study Assessing the Effects of XXXXX and XXXXX in the Improvement of Moderate to Severe Age-Related Skin Changes in Post-menopausal Women Principal Investigator: A 6-month Open-Label, Multi-National Effectiveness, and Safety Study of XXXXX cream 1% in Subjects with Atopic Dermatitis Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXXX Foam, 0.05% in the treatment of Mild to Moderate Plaque-type Psoriasis of Non-Scalp Regions Principal Investigator: Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of XXXXX 5% Cream Applied Once Daily 2 Days per Week for the Treatment of Actinic Keratoses on the Head Principal Investigator: A Phase I-II, Open Label, Multiple-Dose Pharmacokinetic, Pharmacodynamic, and Safety Study of Humanized XXXXX Antibody in Patients with Psoriasis Principal Investigator: A Phase I Multi Dose, Dose-Escalation Study to Evaluate the Safety of XXXXX, a Humanized Monoclonal Antibody That Binds to CD2 Receptor, Administered by Subcutaneous Injection to Patients with Plaque Psoriasis Principal Investigator: A Phase II Randomized, Placebo-Controlled, Double-Blind Study of XXXXX, A Humanized Monoclonal Antibody That Binds to CD2 Receptor, Administered by Subcutaneous Injection to Patients with Plaque Psoriasis
Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of XXXXX 0.03% vs. Vehicle Ointment in Pediatric Patients with Mild to Moderate Atopic Dermatitis Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of a XXXXX Topical Patch in the Treatment of Distal and Subungual Onychomycosis of the Great Toenail Principal Investigator: A Multi-Center, Double-Blind, Placebo Controlled, Parallel Group Study Comparing the Bioequivalence of XXXXX 0.75% and XXXXX 0.75% in the Treatment of Inflammatory Papules and Pustules of Rosacea Principal Investigator: An Open-Label, Multi-Center, Phase IV Study of XXXXX for the treatment of Mild and Moderate Acne Vulgaris. Principal Investigator: A Randomized, Double-Blind, Double-Dummy, Placebo- Controlled Study of the Safety and Efficacy of XXXXX, 2% versus XXXXX 2% Cream in the Treatment of Seborrheic Dermatitis Principal Investigator: A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Trial to Assess the Safety and Efficacy of 0.1% XXXXX in the Treatment of Psoriasis on the Face or Intertriginous (Inverse) Areas Principal Investigator: The Safety and Efficacy of XXXXX Gel, 0.3% as Compared to XXXXX Gel, 0.1% and XXXXX Gel, Vehicle in the Treatment of Acne Vulgaris Principal Investigator: A 12-month, Multicenter, Open-Label, Non-Comparative Design Study of 5% XXXXX Gel in Patients with Acne Vulgaris Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Exploratory Pharmacogenomic Study of Recombinant Human Interleukin XXXXX in Patients with Active Psoriasis Principal Investigator: Phase II//III Multicenter Study of the Safety and Efficacy of XXXXX in Psoriasis Principal Investigator: The XXXXX Cream B.E.S.T. in Acne Trial Principal Investigator: A Phase III Evaluator-Blind, Randomized, Parallel-Group Study to Determine the Effect of the XXXXX Patch, XXXXX 2 mg., on the Healing of Recurrent Minor Aphthous Ulcers as Compared with XXXXX or No Treatment Principal Investigator: A Multi-Center, Double-Barrier, Vehicle-Controlled Study of the Efficacy and Safety of XXXXX Shampoo and XXXXX Shampoo in the Three Times Weeky Treatment of Seborrheic Dermatitis of the Scalp for 4 weeks Principal Investigator: A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of XXXXX in the Treatment of Chronic Plaque Psoriasis Principal Investigator: A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter, Efficacy and Safety Study of XXXXX Versus XXXXX for the Treatment of Onychomycosis Principal Investigator: A Multi-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study of the Efficacy and Safety of 3 Doses of XXXXX Capsules (XXmg) in the Treatment of Plaque Psoriasis for 8 weeks Principal Investigator: A Multicenter, Open Label Study to Observe the Effect of XXXXX on Joint and Skin Disease in Subjects with Psoriatic Arthritis
Principal Investigator: A 12 Week, Multicenter, Double-Blind, Randomized, Parallel Design Study of XX% XXXXX Topical Gel and Vehicle Control in Patients with Acne Vulgaris Principal Investigator: A Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Multicenter Study to Demonstrate the Safety and Clinical Equivalence of a Generic XXXXX (XXXXX Labs Inc) to XXXXX (XXXXX lotion) Topical lotion XX% (XXXXX Labs Inc.) in the Treatment of Inflammatory Papules and Pustules of Rosacea Principal Investigator: An Open-Label, Long-term Extension Study to Assess the Safety of XXXXX in the Treatment of Psoriasis in Adult Subjects Principal Investigator: A Randomized, Double-Blind, Parallel-Group, Multicenter, Vehicle-Controlled Study of XXXXX 0.1% Cream Once Daily (qd) and Twice Daily (bid) in the Treatment of Plaque-Type Psoriasis Principal Investigator: A Randomized, Double-Blind, Parallel Group, Multicenter, Vehicle-Controlled Study of XXXXX 0.l% Cream Once Daily (qd) and Twice Daily (bid) in the Treatment of Atopic Dermatitis Principal Investigator: A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Determine the Therapeutic Equivalence of Two XXXXX Lotion Formulations in Subjects with Rosacea Principal Investigator: A Phase II, Double Blind, Placebo Controlled Randomized Study of XXXXX Administered by 12 Weekly Intravenous Infusions Principal Investigator: A Randomized, Double-Blind, Double Dummy, Placebo-Controlled Study of the Safety and Efficacy of XXXXX versus XXXXX in the Treatment of Seborrheic Dermatitis Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXXX in the Treatment of Mild to Moderate Plaque-type Psoriasis of Non-Scalp Regions Principal Investigator: A Randomized, Double-Blind,Vehicle-Controlled, Multicenter Trial to Assess The Safety and Efficacy of XXXXX in the Treatment of Psoriasis on the Face or Intertriginous (Inverse) Areas Principal Investigator: Phase IIIb, Open-Label Effectiveness and Safety Study of XXXXX Topical Cream in the Treatment of Actinic Keratoses Principal Investigator: An Open Labeled, Multicenter Efficacy and Tolerability Study of XXXXX and XXXXX; XXXXX and XXXXX; XXXXX and XXXXX; XXXXX and XXXXX in Patients with Acne Vulgaris Principal Investigator: An Open Long-term Extension Study to Assess the Safety of XXXXX in the Treatment of Psoriasis in Adult Subjects Principal Investigator: A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Subcutaneously Administered XXXXX in the Treatment and Re-Treatment of Subjects with Moderate to Severe Plaque Psoriasis Principal Investigator: A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of XXXXX in the Short-Term Treatment of Atopic Dermatitis and to Assess XXXXX in the Long-Term Management of Atopic Dermatitis Principal Investigator: A Phase IV, Multicenter, Open-Label, Randomized Study of the Safety and Efficacy of Low-Dose XXXXX (XXXXX) for the Treatment of Moderate to Severe Plaque-Type Psoriasis
Prinicipal Investigator: A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Extension, Efficacy and Safety Study of XXXXX or XXXXX Placebo Combined with Oral XXXXX in the Treatment of Onychomycosis Principal Investigator: An Open Label, Single Group, Multicenter, Phase 3 Extension Study to Assess the Maintenance Use of XXXXX in the Treatment of Onychomychosis Principal Investigator: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXXXX, XXXXX, in the Treatment of Mild to Severe Atopical Dermatitis Principal Investigator: An Open-Label, Multicenter, Observational Phase IV Trial of XXXXX by Community-based Dermatologists to Assess Effectiveness, Tolerability, and Subject Satisfaction, When Used Once Daily for 12 Weeks as Add-on Therapy or Combination Therapy in Currently Untreated Subjects, with Moderate to Moderately Severe Facial Acne Vulgaris Principal Investigator: A Phase I, Double-Blind, Randomized, Placebo-Controlled,Multicenter Study Evaluating the Safety and Tolerability of a Multidose Regimen of XXXXX Topically Applied to Superficial or Nodular Basal Cell Carcinoma Principal Investigator: XXXXX Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients with Chronic Moderate to Severe Plaque Psoriasis Principal Investigator: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of XXXXX for the Treatment of Atopic Dermatitis Community Service: Multiple Skin Cancer Screenings – American Academy of Dermatology/Lankenau Hospital Lankenau Independent Clinic Volunteer Services Oil of Olay Skin cancer Awareness Training/Screening Program
J. Patrick Cooke // Sr. Project Manager Professional Experience May 2013 – September 2013 // Blast Radius / Wunderman World Health, New York, NY As a Sr. PM at Blast Radius I was responsible for the day-to-day management activities on the entire Novartis Gas-X account, as well as portions of the Novartis Prevacid account. Including but not limited to financial forecasting and budgeting